Cargando…
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
RA is a chronic, debilitating disease in which articular inflammation and joint destruction are accompanied by systemic manifestations including anaemia, fatigue and osteoporosis. IL-6 is expressed abundantly in the SF of RA patients and is thought to mediate many of the local and systemic effects o...
Autores principales: | Dayer, Jean-Michel, Choy, Ernest |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789585/ https://www.ncbi.nlm.nih.gov/pubmed/19854855 http://dx.doi.org/10.1093/rheumatology/kep329 |
Ejemplares similares
-
Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis
por: Choy, Ernest H S, et al.
Publicado: (2018) -
Interleukin-6 in Rheumatoid Arthritis
por: Pandolfi, Franco, et al.
Publicado: (2020) -
Interleukin 6 and Rheumatoid Arthritis
por: Yoshida, Yuji, et al.
Publicado: (2014) -
Interleukin-6 inhibitors in the treatment of rheumatoid arthritis
por: Hennigan, Stephanie, et al.
Publicado: (2008) -
Interleukin-18: a therapeutic target in rheumatoid arthritis?
por: McInnes, Iain B, et al.
Publicado: (2005)